← Back to Clinical Trials
Recruiting NCT06502431

NCT06502431 Analysis of Disturbances in Neurofluid Dynamics in Type I Chiari Malformations

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06502431
Status Recruiting
Phase
Sponsor Centre Hospitalier Universitaire, Amiens
Condition Type I Chiari Malformation
Study Type INTERVENTIONAL
Enrollment 60 participants
Start Date 2024-06-24
Primary Completion 2025-04-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 50 Years
Study Type INTERVENTIONAL
Interventions
phase contrast sequences

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 60 participants in total. It began in 2024-06-24 with a primary completion date of 2025-04-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

A global analysis of craniospinal hemodynamics and hydrodynamics is necessary to better understand the pathophysiology of Chiari malformations. This includes an analysis of intraventricular CSF flow, intracranial subarachnoid spaces, foramen magnum, cervical subarachnoid spaces and within the syringomyelia cavity when present. The investigators will also analyze the pulsatility of the cerebellar tonsils in the foramen magnum. Hemodynamic analysis will be performed at the high cervical level (internal carotid and vertebral arteries, jugular veins) and intracranially (carotid and basilar arteries, right sinus and superior longitudinal sinus). This analysis will be made possible by PCMRI acquisitions with slice planes allowing the analysis of the dynamics of the CSF (mesencephalic aqueduct, prepontic cisterns, foramen magnum, at the level of the C2C3 disc, syringomyelia if present), cerebellar tonsils (foramen magnum). The cross-sectional planes for hemodynamic analysis will be at the level of the C2C3 disc (cervical vascular analysis) and upstream of the polygon of Willis (intracranial vascular analysis). The goal is to complement the clinical and morphological investigations with quantitative imaging of cerebrospinal fluid (CSF) and blood flow in the craniospinal system. These flows are potentially altered or causes of this Chiari anomaly. The investigators propose a translational research project of clinical research allowing the analysis of a diagnostic technique by a diagnostic, monocentric, prospective study. After neurosurgical consultation, patients with Chiari malformation will be assigned to a symptomatic Chiari malformation or a non-symptomatic Chiari malformation group. They will be offered to participate in this study after information and informed consent. The allocation between the two groups will be made according to the symptomatic or non-symptomatic nature of the Chiari malformation. After inclusion, the patients will have a morphological MRI and a PCMRI according to the determined slice plans and allowing a global analysis of the craniospinal hemohydrodynamics. Craniospinal hemohydrodynamics in a control population will also be analyzed using the same methodology by PCMRI.

Eligibility Criteria

Inclusion Criteria: * All patients with major symptomatic or nonsymptomatic CMI * aged 18 to 50 years * no previous neurosurgical, neurological, or cardiological history. * Controls should be age-matched to symptomatic CMI group. They should not have a history of neurosurgery, neurology, or cardiology. Exclusion Criteria: * Patients who are minors or over 50 years of age * CMI invalidated by our radiological review * Neurosurgical, neurological or cardiological history * MRI contraindication * pregnant, breast-feeding and parturient women

Contact & Investigator

Central Contact

Cyrille Capel, MD

✉ capel.cyrille@chu-amiens.fr

📞 0322088947

Frequently Asked Questions

Who can join the NCT06502431 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 50 Years, studying Type I Chiari Malformation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06502431 currently recruiting?

Yes, NCT06502431 is actively recruiting participants. Contact the research team at capel.cyrille@chu-amiens.fr for enrollment information.

Where is the NCT06502431 trial being conducted?

This trial is being conducted at Amiens, France.

Who is sponsoring the NCT06502431 clinical trial?

NCT06502431 is sponsored by Centre Hospitalier Universitaire, Amiens. The trial plans to enroll 60 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology